Brawn Biotech (BOM:530207) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Brawn Biotech Debt-to-Equity?

Brawn Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹0.0 Mil. Brawn Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹0.0 Mil. Brawn Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹50.7 Mil. Brawn Biotech's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Brawn Biotech's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Brawn Biotech was 0.02. The lowest was 0.02. And the median was 0.02.

BOM:530207's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Brawn Biotech Debt-to-Equity Historical Data

The historical data trend for Brawn Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brawn Biotech Debt-to-Equity Chart

Brawn Biotech Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

Brawn Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	N/A	-	N/A	-

Competitive Comparison of Brawn Biotech's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Brawn Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brawn Biotech's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brawn Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Brawn Biotech's Debt-to-Equity falls into.

Brawn Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Brawn Biotech's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	50.65
	=	0.00

Brawn Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	50.65
	=	0.00

Brawn Biotech (BOM:530207) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Brawn Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Brawn Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Brawn Biotech (BOM:530207) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Brawn Biotech Ltd (BOM:530207) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Plot No. 30, Sector 33, Near Hero Honda Factory, Gurugram, HR, IND, 122001

Website

https://www.brawnbiotech.com

Brawn Biotech Ltd is a healthcare company. It is primarily engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals. It markets pharmaceutical products in India and internationally. The company generates a major portion of its revenue from exports.

Brawn Biotech (BOM:530207) Headlines

No Headlines